Skip to main content
. 2014 Oct 2;26(4):946–956. doi: 10.1681/ASN.2014010108

Table 2.

Baseline demographic, clinical, and biochemical characteristics of CRIC Study participants without HF at baseline by quintile of NT-proBNP

Characterisitics NT-proBNP Quintile (n), pg/mla P Value
≤47.6 (n=697) >47.6–95.8 (n=697) >95.8–188.8 (n=696) >188.8–433.0 (n=697) >433.0 (n=696)
Age, yr 52.9 (11.7) 57.2 (10.8) 58.9 (11.2) 59.9 (10.5) 60.5 (10.0) <0.001
Women 232 (33.3%) 330 (47.3%) 338 (48.6%) 370 (53.1%) 317 (45.5%) <0.001
Race/ethnicity <0.001
 Non-Hispanic white 300 (43.0%) 306 (43.9%) 325 (46.7%) 309 (44.3%) 252 (36.2%)
 Non-Hispanic black 317 (45.5%) 295 (42.3%) 264 (37.9%) 254 (36.4%) 263 (37.8%)
 Hispanic 45 (6.5%) 62 (8.9%) 88 (12.6%) 103 (14.8%) 157 (22.6%)
 Other 35 (5.0%) 34 (4.9%) 19 (2.7%) 31 (4.4%) 24 (3.4%)
eGFR, ml/min per 1.73 m2b 58.1 (16.8) 49.7 (16.4) 45.2 (15.3) 40.6 (13.8) 35.0 (12.4) <0.001
24-hour urine protein, g/d 0.1 (0.06–0.3) 0.1 (0.07–0.6) 0.2 (0.07–0.7) 0.2 (0.08–1.1) 0.7 (0.1–2.8) <0.001
Diabetes 218 (31.3%) 291 (41.8%) 315 (45.3%) 362 (51.9%) 429 (61.6%) <0.001
History of MI/stroke/PAD 79 (11.3%) 121 (17.4%) 172 (24.7%) 215 (30.8%) 323 (46.4%) <0.001
Current smoker 66 (9.5%) 76 (10.9%) 83 (11.9%) 99 (14.2%) 124 (17.8%) <0.001
Alcohol use 511 (73.3%) 496 (71.2%) 433 (62.2%) 419 (60.1%) 371 (53.3%) <0.001
Body mass index, kg/m2 31.8 (6.6) 32.0 (7.5) 32.1 (8.4) 32.0 (8.3) 31.6 (7.7) 0.76
Systolic BP, mmHg 118.9 (15.2) 124.0 (18.5) 125.0 (18.7) 131.8 (22.0) 142.5 (26.1) <0.001
Diastolic BP, mmHg 73.0 (11.1) 72.4 (11.4) 70.1 (11.8) 71.3 (13.2) 72.7 (14.9) <0.001
Hemoglobin, g/dl 13.6 (1.6) 12.9 (1.5) 12.6 (1.6) 12.3 (1.7) 11.8 (1.9) <0.001
LDL cholesterol, mg/dl 107.7 (34.0) 104.5 (35.0) 104.0 (35.5) 101.8 (34.1) 101.2 (37.8) 0.005
HDL cholesterol, mg/dl 47.1 (14.2) 48.2 (15.3) 49.0 (15.8) 48.8 (16.8) 46.7 (15.7) 0.02
ACE/ARB use 457 (66.2%) 467 (67.6%) 479 (69.1%) 481 (69.5%) 458 (66.3%) 0.56
Diuretic use 292 (42.3%) 369 (53.4%) 404 (58.3%) 401 (57.9%) 482 (69.8%) <0.001
β-Blocker use 157 (22.8%) 242 (35.0%) 305 (44.0%) 405 (58.5%) 482 (69.8%) <0.001
FGF23, RU/ml 99.6 (73.4–144.8) 122.7 (86.2–183.7) 133.2 (94.6–206.0) 159.3 (107.4–244.5) 209.1 (136.2–344.0) <0.001
Serum phosphorus, mg/dl 3.5 (0.6) 3.6 (0.6) 3.7 (0.7) 3.8 (0.7) 3.9 (0.7) <0.001
Total PTH, pg/ml 41.0 (29.4–56.0) 47.8 (32.6–77.3) 51.5 (32.0–78.6) 57.0 (37.0–94.0) 74.0 (46.0–123.4) <0.001
EF from echocardiogramc 55.6 (6.4) 56.1 (6.1) 55.6 (7.0) 54.8 (7.7) 52.2 (9.5) <0.001
LVMI, g/m2.7c 45.3 (10.4) 48.6 (11.4) 49.9 (12.3) 52.4 (13.2) 59.7 (15.4) <0.001

MI, myocardial infarction; PAD, peripheral arterial disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; RU, relative units.

a

NT-proBNP categories were defined by quintiles.

b

eGFR calculated using serum creatinine and cystatin C (47).

c

From the year 1 clinic visit.